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Abstract 
Importance: Limited empirical research has examined the extent to which cohort-level prevalence of 
substance use is associated with the onset of drug use and transitioning into greater involvement with 
drug use. 
Objective: To use cross-national data to examine time-space variation in cohort-level drug use to assess 
its associations with onset and transitions across stages of drug use, abuse, dependence, and remission. 
Design, Setting, and Participants: The World Health Organization World Mental Health Surveys carried out 
cross-sectional general population surveys in 25 countries using a consistent research protocol and 
assessment instrument. Adults from representative household samples were interviewed face-to-face in 
the community in relation to drug use disorders. The surveys were conducted between 2001 and 2015. 
Data analysis was performed from July 2017 to July 2018. 
Main Outcomes and Measures: Data on timing of onset of lifetime drug use, DSM-IV drug use disorders, 
and remission from these disorders was assessed using the Composite International Diagnostic 
Interview. Associations of cohort-level alcohol prevalence and drug use prevalence were examined as 
factors associated with these transitions. 
Results: Among the 90 027 respondents (48.1% [SE, 0.2%] men; mean [SE] age, 42.1 [0.1] years), 1 in 4 
(24.8% [SE, 0.2%]) reported either illicit drug use or extramedical use of prescription drugs at some point 
in their lifetime, but with substantial time-space variation in this prevalence. Among users, 9.1% (SE, 0.2%) 
met lifetime criteria for abuse, and 5.0% (SE, 0.2%) met criteria for dependence. Individuals who used 2 or 
more drugs had an increased risk of both abuse (odds ratio, 5.17 [95% CI, 4.66-5.73]; P < .001) and 
dependence (odds ratio, 5.99 [95% CI, 5.02-7.16]; P < .001) and reduced probability of remission from 
abuse (odds ratio, 0.86 [95% CI, 0.76-0.98]; P = .02). Birth cohort prevalence of drug use was also 
significantly associated with both initiation and illicit drug use transitions; for example, after controlling 
for individuals’ experience of substance use and demographics, for each additional 10% of an individual’s 
cohort using alcohol, a person’s odds of initiating drug use increased by 28% (odds ratio, 1.28 [95% CI, 
1.26-1.31]). Each 10% increase in a cohort’s use of drug increased individual risk by 12% (1.12 [95% CI, 
1.11-1.14]). 
Conclusions and Relevance: Birth cohort substance use is associated with drug use involvement beyond 
the outcomes of individual histories of alcohol and other drug use. This has important implications for 
understanding pathways into and out of problematic drug use. 
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IMPORTANCE Limited empirical research has examined the extent to which cohort-level
prevalence of substance use is associated with the onset of drug use and transitioning into
greater involvement with drug use.
OBJECTIVE To use cross-national data to examine time-space variation in cohort-level drug
use to assess its associations with onset and transitions across stages of drug use, abuse,
dependence, and remission.
DESIGN, SETTING, AND PARTICIPANTS The World Health Organization World Mental Health
Surveys carried out cross-sectional general population surveys in 25 countries using a
consistent research protocol and assessment instrument. Adults from representative
household samples were interviewed face-to-face in the community in relation to drug use
disorders. The surveys were conducted between 2001 and 2015. Data analysis was
performed from July 2017 to July 2018.
MAIN OUTCOMES AND MEASURES Data on timing of onset of lifetime drug use, DSM-IV drug
use disorders, and remission from these disorders was assessed using the Composite
International Diagnostic Interview. Associations of cohort-level alcohol prevalence and drug
use prevalence were examined as factors associated with these transitions.
RESULTS Among the 90 027 respondents (48.1% [SE, 0.2%] men; mean [SE] age, 42.1 [0.1]
years), 1 in 4 (24.8% [SE, 0.2%]) reported either illicit drug use or extramedical use of
prescription drugs at some point in their lifetime, but with substantial time-space variation in
this prevalence. Among users, 9.1% (SE, 0.2%) met lifetime criteria for abuse, and 5.0% (SE,
0.2%) met criteria for dependence. Individuals who used 2 or more drugs had an increased
risk of both abuse (odds ratio, 5.17 [95% CI, 4.66-5.73]; P < .001) and dependence (odds ratio,
5.99 [95% CI, 5.02-7.16]; P < .001) and reduced probability of remission from abuse (odds
ratio, 0.86 [95% CI, 0.76-0.98]; P = .02). Birth cohort prevalence of drug use was also
significantly associated with both initiation and illicit drug use transitions; for example, after
controlling for individuals’ experience of substance use and demographics, for each additional
10% of an individual’s cohort using alcohol, a person’s odds of initiating drug use increased by
28% (odds ratio, 1.28 [95% CI, 1.26-1.31]). Each 10% increase in a cohort’s use of drug
increased individual risk by 12% (1.12 [95% CI, 1.11-1.14]).
CONCLUSIONS AND RELEVANCE Birth cohort substance use is associated with drug use
involvement beyond the outcomes of individual histories of alcohol and other drug use. This
has important implications for understanding pathways into and out of problematic drug use.
JAMA Psychiatry. 2019;76(7):708-720. doi:10.1001/jamapsychiatry.2019.0163
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Improved understanding of determinants of drug use dis-orders (DUDs) and transitions through different levels ofinvolvement is important to assist in identifying critical pe-
riods when specific interventions may be best targeted and
shed light on potential factors that may affect such trajecto-
ries. Research on trajectories of drug use has most often con-
sidered the transition between use and dependence1,2 or fo-
cused on specific populations, such as people in treatment
for DUDs.3-5
The general population studies that have explored the
natural history of substance use show that social contextual
risk factors have differential roles in each transition stage.2,6-10
For example, substance use is linked to social and peer-level
variables11; and evidence suggests that the extent to which be-
havior is normative may be associated with adverse sub-
stance use outcomes (with people engaging in less normative
behavior having a greater likelihood of problematic sub-
stance use).12,13
Previous studies have found that chronological age, his-
torical period, and birth cohort effects are associated with dif-
ferences in substance use and associated problems.14-17 Dif-
ferences by age group in substance use and associated problems
have often been attributed at least in part to developmental
and maturational factors,11 especially when cross-sectional
comparisons are made between age groups within a sample
of a population that covers a broad age range.18-20
However, individuals are also strongly influenced by the
broader social context in which they live. Substance use in-
fluences (eg, substance use norms, enforcement of sanctions
against drug use, drug availability, and perceptions of risk),
have varied widely across geographical locations and in dif-
ferent periods in history. Cohort effects include the shared so-
cial and environmental influences on individuals born at par-
ticular times as they mature, experiencing the extant period
effects, including changes in period effects over time. There
are complex issues involved in distinguishing period and co-
hort effects,21,22 and although there is evidence of both influ-
ences, research has shown that substance use behaviors are
especially associated with cohort effects,17,23,24 which may
modify period effects and perhaps have other social influ-
ences. Supporting this possibility, we previously used a na-
tional study of Australian adults to investigate associations of
levels of involvement with alcohol and cannabis use with birth
cohort use25 and found that the level of alcohol or cannabis
use within an individual’s age cohort was associated with risks
of progressing further into involvement with alcohol and can-
nabis use, respectively.25
In this article, we present (for the first time, to our knowl-
edge) country-level data on lifetime prevalence of illicit
drug use, DSM-IV DUDs (including drug abuse and depen-
dence), and remission from DUDs. We also conduct the first-
ever analyses of the influence of cohort effects on individu-
als’ drug use cross-nationally using the World Health
Organization (WHO) World Mental Health (WMH) Surveys
(https://www.hcp.med.harvard.edu/wmh/),26 a unique
database made up of 27 population surveys conducted in 25
countries across the globe. We examine the extent to which
an individual’s birth cohort’s use of both alcohol and drugs at
various points in the life course is associated with the individual
transitioning across levels of involvement with drug use net
of the outcomes of the individual’s own history of substance
use at that point in time.
Method
Sample
Data come from 27 WMH surveys that assessed DUDs. Six sur-
veys were conducted in countries classified by the World Bank
at time of data collection as having low or lower-middle in-
come levels (Colombia [national], Iraq, Nigeria, People’s Re-
public of China, Peru, and Ukraine), 6 surveys in 6 countries
classified as having upper-middle income levels (Brazil, Bul-
garia, Colombia [Medellín region only], Lebanon, Mexico, and
South Africa), and 15 surveys in 14 in countries classified as hav-
ing high income levels (Argentina, Australia, Belgium, France,
Germany, Israel, Italy, Japan, Netherlands, New Zealand, North-
ern Ireland, Poland, Spain [including separate national and re-
gional surveys], and the United States). Most surveys were
based on nationally representative household samples. The
sample characteristics for all participating surveys are shown
in eTable 1 in the Supplement.
Informed consent was obtained before beginning inter-
views in all countries. Procedures for obtaining informed con-
sent and protecting participants were approved and moni-
tored by the institutional review boards of organizations
coordinating surveys in each country. Full details of the WMH
surveys have been published previously26-30 and are summa-
rized in the eMethods in the Supplement (which also refer-
ences eTables 14 and 15 in the Supplement).
Data Analysis
Age at onset and speed of transition between various drug
stages were examined. These stages were use (the first time
using any drug), DSM-IV abuse, DSM-IV dependence, remis-
sion from abuse without dependence (defined as absence of
all abuse symptoms for more than 12 months at the time of the
Key Points
Question Is the extent to which alcohol and other drugs are used
in an individual’s birth cohort associated with an individual’s risk
of commencing drug use, transitioning to problematic use, and
entering remission?
Findings This study of cross-national data of 90 027 respondents
from the World Mental Health Surveys found that an individual’s
personal risk of transitioning to greater involvement with drug use
is associated with the substance use histories of their age cohort,
as well as their own history of involvement with drugs and alcohol.
Results were statistically significant after controlling for
sociodemographic factors and were consistent across country
income levels.
Meaning Per this analysis, any intervention to reduce substance
use within a cohort may also reduce individual-level risk for
transitioning into greater levels of involvement with drug use.
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interview), and remission from dependence (defined as an ab-
sence of all dependence symptoms for more than 12 months
at the time of the interview). To improve cross-national com-
parability, all survey data were restricted to persons 18 years
and older at the time of the interview.
All analyses were carried out in SAS version 9.4 (SAS In-
stitute) using weighted data and accounting for the complex
survey design features, namely stratification and clustering.
Person weights were used to adjust for probability of selec-
tion, nonresponse and poststratification factors, and part II data
weights adjusted for oversampling of part I respondents with
mental disorders. These weighting procedures ensured that all
samples are representative of the population of the survey
country or region at the time of data collection.
Life-table (actuarial) estimates of the survival functions for
age at onset and remission were produced using the SAS PROC
LIFETEST procedure and are reported as weighted preva-
lence. Discrete-time logistic regression models were used to
investigate the outcome of cohort and individual substance use
variables on the commencement of illicit drug use and tran-
sitions from use to disorder (abuse and dependence) and dis-
order to remission (among participants with a valid age at on-
set of remission; eMethods in the Supplement). These analyses
were conducted in SAS PROC SURVEYLOGISTIC using person-
year as the unit of analysis and a logistic link function.
Person-year data sets were created in which each year in
the life of each respondent during which they were at risk of
transitioning, from the age at onset of the initial stage up to
the age at onset of the transition or age at interview (which-
ever came first), was treated as a separate observational rec-
ord. The year of transition was coded 1 and earlier years coded
0 on a dichotomous response variable. Survival coefficients
and standard errors are presented as odds ratios (ORs) and 95%
CIs. Multivariable significance tests were made with Wald χ2
tests using Taylor series design–based coefficient variance-
covariance matrices and significance evaluated at .05 with
2-sided tests.
A country-specific or region-specific contextual variable
representing cumulative lifetime prevalence of substance use
in the individual’s birth cohort at each year of life was con-
structed and used to assess transitioning to each drug stage.
An individual’s birth cohort was based on their year of birth
±5 years, which created 11-year-wide survey-specific cohorts
centered around their year of birth. The cohort widths were
reduced for those aged between 18 and 22 years as close as pos-
sible to ensure symmetry around birth year; the total band
width size was 2 years for 18-year-olds (18-19 years), 3 years
for 19-year-olds (18-20 years), 5 years for 20-year-olds (18-22
years), 7 years for 21-year-olds (18-24 years) and 9 years for
22-year-olds (18-26 years). Cohorts were topcoded for those
65 years or older. The independent variable was the esti-
mated proportion (divided by 10) of people in the individu-
al’s birth cohort who had used the specific substance (either
alcohol or drugs) as of each prior year of age; in this way, it cap-
tured the percentage of people in the cohort who had already
commenced use at any given age. To capture only the most
prominent changes in cohort use, cohort use prevalence was
set to 0 for person years younger than 12 years and topcoded
for those 30 years and older. Linearity of the cohort use vari-
ables were investigated.
To investigate the outcome of the individual’s own prior
involvement with alcohol on risk of drug transitions, 4 mutu-
ally exclusive, time-varying dummy variables were included
as factors for highest lifetime-to-date level of alcohol involve-
ment (none vs either use, abuse, dependence, or remission
from abuse or dependence). In addition, models for transi-
tions after first use considered the types of drugs being used,
with indicators for onset of cannabis, cocaine, and other drug
use (prescription drugs combined with the category “other
drugs” owing to small numbers) as well as whether 2 or more
of these drug categories had been used. A total of 6 models in-
vestigating cohort and individual substance involvement were
investigated: (1) prevalence of cohort drug use, (2) preva-
lence of cohort alcohol use, (3) individuals’ level of alcohol
involvement, (4) type of drugs, (5) number of drugs, and
(6) all cohort and individual substance variables. All models
adjusted for a wide range of variables (eMethods in the
Supplement). Data analysis was performed from July 2017 to
July 2018.
Results
Combining participants from all 27 surveys, 90 093 respon-
dents were administered the drug module. Sixty-six respon-
dents (35 from Israel, 15 from Mexico, 11 from Japan, and 5 from
South Africa) provided no valid answers to any drug use ques-
tion and were excluded. Therefore, a total of 90 027 respon-
dents are included in the analyses.
Prevalence of Use, Abuse, Dependence, Use Disorders,
and Remission
Lifetime prevalence estimates for use of any drug and spe-
cific drugs are shown in Table 1. Across countries, 24.8% (SE,
0.2%) of respondents reported lifetime illicit drug use or ex-
tramedical use of prescription drugs. Within each country in-
come grouping, cannabis was the most commonly used drug
of those considered; the United States (42.3% [SE, 1.0%]) and
New Zealand (41.9% [SE, 0.7%]) had the highest lifetime
cannabis prevalence. The United States (16.2% [SE, 0.6%])
and Murcia (Spain, 7.8% [SE, 1.1%]) had the highest lifetime
prevalence of cocaine use. Highest estimates of extramedical
prescription drug use were observed in some countries in
Europe, including Italy (66.0% [SE, 0.2%]), Germany (62.3%
[SE, 2.5%]), Spain (61.5% [SE, 2.6%]), Belgium (43.5% [SE,
3.0%]), and France (43.4% [SE, 2.0%]), whereas Iraq (1.3% [SE,
0.2%]), China (5.9% [SE, 0.9%]), Lebanon (6.2% [SE, 1.1%]),
Japan (7.0% [SE, 0.8%]), and Bulgaria (7.3% [SE, 0.8%]) had
the lowest rates of any drug use.
Table 2 shows prevalence estimates of lifetime DUDs over-
all and conditional on ever having used drugs, as well as re-
mission rates overall and among those with the specific use
disorders. The lifetime prevalence of drug abuse and drug de-
pendence in the total sample were 2.2% (SE, 0.1%) and 1.2%
(SE, 0.1%), respectively (Table 2). Again, there was consider-
able geographic variation. Around 1 in 7 drug users devel-
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oped a DUD (14.0% [SE, 0.3%]), with the rate of abuse (9.1%
[SE, 0.2%]) higher than dependence (5.0% [SE, 0.2%]). Re-
mission prevalence rates for the entire cohort were 1.8% (SE,
0.1%) for abuse and 0.9% (SE, <0.1%) for dependence. Condi-
tional remission estimates were 78.0% (SE, 1.1%) for drug abuse
and 70.7% (SE, 1.7%) for drug dependence.
Age at Onset and Time to Transition Across Stages
of Involvement
The Figure shows the cumulative age at onset curves for
onset of illicit drug use, abuse, dependence, remission from
abuse and remission from dependence (Figure, A), and
the cumulative time to transition between drug stages
(Figure, B). Onset of drug use largely occurred during the
late teenage years (median [interquartile range; IQR]
age at onset, 19 [16-24] years). For DUDs, the median (IQR)
age at onset was slightly earlier for abuse (20 [18-25] years )
than dependence (21 [18-26] years). This was similar for
remission, with the median age at onset of remitting
from abuse 1 year younger than the median age at onset of
dependence remission (28 [IQR, 23-37] years vs 29 [IQR,
24-36] years).
Table 1. Lifetime Prevalence of Overall Drug Use and Specific Drug Use in the World Mental Health Surveys
Countrya No.b
% (SE)c
Cannabis Cocaine Prescription Drugsd Other Drugs Any Drugse,f
Low and lower-middle
income
18 179 5.3 (0.2) 2.0 (0.1) 4.7 (0.2) 0.6 (0.1) 10.0 (0.3)
Colombia 4426 10.8 (0.6) 4.0 (0.4) 2.2 (0.3) 0.9 (0.2) 12.7 (0.7)
Iraq 4332 0.0 (0.0) 0.0 (0.0) 1.2 (0.2) 0.1 (0.0) 1.3 (0.2)
Nigeria 2143 2.7 (0.5) 0.1 (0.1) 18.7 (1.3) 0.5 (0.2) 20.4 (1.3)
Peru 3930 7.9 (0.4) 4.8 (0.2) 4.3 (0.3) 1.0 (0.1) 13.3 (0.5)
China 1628 0.3 (0.1) 0.0 (0.0) 5.8 (0.9) 0.2 (0.2) 5.9 (0.9)
Ukraine 1720 6.4 (1.0) 0.1 (0.0) 2.4 (0.6) 0.8 (0.2) 8.4 (1.2)
Upper-middle income 20 051 9.2 (0.3) 3.1 (0.2) 7.8 (0.4) 1.5 (0.1) 16.2 (0.5)
Brazil 5037 11.8 (0.7) 5.2 (0.4) 6.9 (0.3) 2.5 (0.3) 17.6 (0.7)
Bulgaria 2233 1.3 (0.5) 0.0 (0.0) 6.1 (0.6) 0.0 (0.0) 7.3 (0.8)
Lebanon 1031 4.6 (0.9) 0.7 (0.3) 2.0 (0.6) 0.3 (0.2) 6.2 (1.1)
Medellín 1673 21.9 (1.9) 6.3 (0.9) 2.7 (0.6) 1.8 (0.4) 22.7 (1.9)
Mexico 5767 7.8 (0.5) 4.0 (0.4) 1.8 (0.3) 1.0 (0.2) 10.1 (0.5)
South Africa 4310 8.4 (0.6) 0.7 (0.3) 21.5 (1.5) 1.7 (0.3) 27.2 (1.7)
High income 51 797 24 (0.3) 4.4 (0.1) 13.6 (0.2) 6.2 (0.2) 33.3 (0.3)
Argentina 2116 14.2 (1.0) 5.8 (0.6) 14.4 (1.1) 3.3 (0.5) 26.3 (1.3)
Australia 8463 19.8 (0.6) 2.9 (0.3) 2.5 (0.2) 7.3 (0.4) 21.4 (0.6)
Belgium 1043 10.4 (1.6) 1.5 (0.6) 43.5 (3.0) 2.8 (0.8) 47.6 (2.8)
France 1436 19 (1.6) 1.5 (0.4) 43.4 (2.0) 4.8 (0.7) 52.7 (1.7)
Germany 1323 17.5 (1.6) 1.9 (0.5) 62.3 (2.5) 3.4 (0.7) 66.4 (2.5)
Israel 4824 11.5 (0.5) 0.9 (0.1) 1.7 (0.2) 1.8 (0.2) 12.9 (0.5)
Italy 1779 6.6 (0.8) 1.0 (0.3) 66.0 (2.0) 0.9 (0.2) 66.8 (2.0)
Japan 1671 1.5 (0.4) 0.5 (0.2) 4.8 (0.7) 1.8 (0.5) 7.0 (0.8)
Murcia, Spain 1459 23.1 (1.3) 7.8 (1.1) 0.9 (0.5) 3.1 (0.8) 24.2 (1.5)
Netherlands 1094 19.8 (1.3) 1.9 (0.2) 20.1 (2.4) 4.1 (0.8) 35.9 (2.4)
New Zealand 12 790 41.9 (0.7) 4.3 (0.3) 6.6 (0.3) 10.2 (0.4) 42.9 (0.7)
Northern Ireland 1986 17.3 (1.1) 3.5 (0.5) 2.3 (0.4) 4.5 (0.7) 18.2 (1.2)
Poland 4000 3.8 (0.3) 0.4 (0.1) 5.1 (0.3) 1.5 (0.2) 8.7 (0.5)
Spain 2121 15.9 (1.3) 4.1 (0.7) 61.5 (2.6) 3.5 (0.7) 64.5 (2.6)
United States 5692 42.3 (1.0) 16.2 (0.6) 11.3 (0.5) 11.1 (0.6) 44.2 (1.1)
All 90 027 16.9 (0.2) 3.6 (0.1) 10.5 (0.2) 4.0 (0.1) 24.8 (0.2)
a County income group reflects economic development status at time of data
collection based on the World Bank country level ranking.
b Indicates the total unweighted number of respondents who responded to
illicit drug use question(s).
c Prevalence estimates are based on weighted data.
d All European Study of the Epidemiology of Mental Disorders surveys (Belgium,
France, Germany, Italy, Netherlands and Spain) asked 3 separate questions on
extramedical use (on whether it was used without a prescription, more than
prescribed, and so regularly in a nonmedical setting that you could not stop)
for each prescription drug category. In contrast, most other surveys asked a
single question pertaining to extramedical use of specific or any prescription
drugs. The more detailed question structure in the European Study of the
Epidemiology of Mental Disorders interviews is likely the reason for the high
rates of prescription drug use in these surveys.
e Respondents were included in the category “any drugs” if they provided
information relating to the use of at least 1 drug.
f Used at least 1 of the drug categories considered: cannabis, cocaine,
prescription drugs, and other drugs. Any drugs not captured by the first
3 categories were grouped as other drugs.
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The transition from initial use to DUD onset was often fast,
with 54.7% (95% CI, 54.5-54.8) of all users who developed
abuse doing so within 3 years of first use. Median (IQR) time
to dependence was slightly longer, at 5 (2-8) years from first
use. Among those that eventually remitted, median (IQR) time
with the disorder was slightly longer for dependence at
6 (4-11) years, compared with abuse at 5 (3-9) years.
Factors Associated With Transitions Between Stages
of Drug Involvement
Table 3 summarizes the results of 5 models investigating the
association of each substance variable with transitions be-
tween stages of drug involvement, with adjustment for all so-
ciodemographic variables. (Complete set of results are shown
in eTables 2-7 in the Supplement.)
Table 2. Conditional Lifetime Prevalence of DSM-IV Drug Use Disorders and Remission in the World Mental Health Surveysa
Countryd No.e






























18 179 0.6 (0.1) 0.3 (0.0) 0.5 (0.1) 0.2 (0) 6.1 (0.6) 3.2 (0.5) 9.3 (0.9) 75 (5.5) 56.4 (6.7)
Colombia 4426 0.9 (0.2) 0.8 (0.2) 0.7 (0.1) 0.4 (0.1) 6.8 (1.3) 6.4 (1.3) 13.2 (2.1) 75 (8.3) 54.7 (7.6)
Iraq 4332 0.1 (0.1) 0.0 (0.0) 0.0 (0.0) 0.0 (0.0) 11.4 (7.6) 0.9 (0.9) 12.3 (7.6) NAh NA
Nigeria 2143 1.0 (0.2) 0.0 (0.0) 0.8 (0.2) 0.0 (0.0) 5.0 (1.1) 0.1 (0.1) 5.1 (1.1) NA NA
Peru 3930 0.8 (0.1) 0.3 (0.1) 0.7 (0.1) 0.1 (0.1) 5.8 (0.8) 2.1 (0.8) 8.0 (1.2) NA NA
China 1628 0.4 (0.2) 0.0 (0.0) 0.4 (0.2) 0.0 (0.0) 7.5 (3.2) 0.2 (0.2) 7.7 (3.2) NA NA
Ukraine 1720 0.4 (0.2) 0.6 (0.2) 0.2 (0.1) 0.4 (0.2) 5.0 (2.5) 6.7 (1.9) 11.7 (2.6) NA NA
Upper-middle
income
20 051 1.7 (0.1) 0.8 (0.1) 1.1 (0.1) 0.5 (0.1) 10.4 (0.7) 4.9 (0.6) 15.3 (0.9) 67.7 (3.2) 64.1 (4.4)
Brazil 5037 1.5 (0.2) 1.4 (0.3) 1.3 (0.2) 0.9 (0.2) 8.6 (1.0) 7.9 (1.6) 16.5 (1.8) 83.1 (5.2) 62.4 (6.3)
Bulgaria 2233 0.2 (0.1) NA 0.2 (0.1) 0.0 (0.0) 2.3 (1.2) 0.0 (0.0) 2.3 (1.2) NA NA
Lebanon 1031 0.3 (0.3) 0.1 (0.1 0.3 (0.3) 0.0 (0.0) 5.6 (4.6) 2.3 (1.5) 7.8 (3.8) NA NA
Medellín 1673 3.4 (0.5) 1.9 (0.4) 2.9 (0.5) 1.1 (0.3) 14.9 (2.2) 8.2 (1.7) 23.1 (2.8) 84.9 (4.6) 57.3 (10.1)
Mexico 5767 0.9 (0.2) 0.5 (0.1) 0.7 (0.1) 0.3 (0.1) 9.1 (1.5) 4.9 (1.1) 14.0 (1.6) 76.6 (6.6) NA
South
Africa
4310 3.4 (0.3) 0.6 (0.2) 1.6 (0.2) 0.5 (0.1) 12.4 (1.4) 2.3 (0.6) 14.7 (1.8) 48.2 (5.6) NA
High income 51 797 3.0 (0.1) 1.7 (0.1) 2.4 (0.1) 1.3 (0.1) 9.1 (0.3) 5.2 (0.2) 14.3 (0.3) 80.5 (1.2) 72.9 (1.9)
Argentina 2116 3.0 (0.5) 1.2 (0.3) 2.1 (0.3) 0.7 (0.2) 11.4 (1.7) 4.4 (1.1) 15.9 (1.9) 68.2 (7) 63.9 (8.5)
Australia 8463 4.6 (0.2) 2.9 (0.3) 4.0 (0.2) 2.3 (0.3) 21.6 (1.2) 13.5 (1.4) 35.1 (1.7) 86.2 (1.8) 79.8 (3.6)
Belgium 1043 3.4 (0.7) 1.1 (0.6) 2.3 (0.5) 0.4 (0.2) 7.1 (1.4) 2.3 (1.3) 9.4 (1.8) 69.2 (13.1) NA
France 1436 2.6 (0.3) 0.9 (0.3) 2.2 (0.2) 0.6 (0.3) 5.0 (0.5) 1.7 (0.5) 6.6 (0.9) 84.3 (2.7) NA
Germany 1323 2.4 (0.5) 0.5 (0.3) 2.2 (0.4) 0.2 (0.1) 3.6 (0.7) 0.7 (0.4) 4.4 (0.8) 90 (6.1) NA
Israel 4824 1.4 (0.2) 0.3 (0.1) 1.1 (0.2) 0.3 (0.1) 10.8 (1.3) 2.3 (0.6) 13.1 (1.4) 81.6 (4.8) NA
Italy 1779 2.1 (0.4) 0.4 (0.1) 1.8 (0.4) 0.3 (0.1) 3.1 (0.6) 0.6 (0.2) 3.7 (0.6) 87.4 (5.9) NA
Japan 1671 0.2 (0.1) 0.0 (0.0) 0.1 (0.1) 0.0 (0.0) 3.0 (1.4) 0.7 (0.5) 3.7 (1.5) NA NA
Murcia 1459 2.4 (0.7) 1.2 (0.4) 1.7 (0.7) 0.6 (0.2) 10.0 (2.4) 5.2 (1.5) 15.2 (2.5) NA NA
Netherlands 1094 1.0 (0.3) 1.1 (0.6) 0.9 (0.3) 1.0 (0.6) 2.9 (0.9) 3.0 (1.7) 5.8 (1.8) NA NA
New
Zealand
12 790 3.1 (0.2) 2.5 (0.2) 2.6 (0.2) 1.6 (0.1) 7.2 (0.5) 5.8 (0.4) 13.0 (0.6) 82.8 (2.3) 65.2 (3.4)
Northern
Ireland
1986 2.7 (0.4) 0.6 (0.2) 1.5 (0.3) 0.4 (0.1) 14.8 (2.3) 3.5 (0.9) 18.4 (2.5) 54.2 (8.6) NA
Poland 4000 1.2 (0.2) 0.2 (0.1) 0.4 (0.1) 0.1 (0.0) 13.5 (1.7) 2.8 (0.9) 16.2 (2.0) 36.8 (7.1) NA
Spain 2121 3.8 (0.5) 0.3 (0.1) 3.2 (0.6) 0.3 (0.1) 5.9 (0.9) 0.5 (0.1) 6.3 (0.9) 84.8 (5.7) NA
United
States
5692 4.9 (0.3) 3.5 (0.2) 4.1 (0.2) 2.9 (0.2) 11.1 (0.7) 7.8 (0.5) 18.9 (0.9) 83.1 (1.7) 83.5 (2.6)
All 90 027 2.2 (0.1) 1.2 (0.1) 1.8 (0.1) 0.9 (0.0) 9.1 (0.2) 5.0 (0.2) 14.0 (0.3) 78 (1.1) 70.7 (1.7)
Abbreviation: NA, not available.
a Disorder and remission diagnoses are for any drug.
b Prevalence estimates are based on weighted data.
c Inclusion in the denominator is conditional on persons having met a certain
level of drug involvement.
d Country income group reflects economic development status at time of data
collection based on the World Bank country level ranking.
e Indicates the total unweighted number of respondents.
f Excludes persons with lifetime drug dependence.
g Remission from abuse excludes persons with lifetime drug dependence.
h Cells marked NA indicate the estimates were not provided because of small
sample sizes (n < 30).
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Cohort-Level Substance Use
In the transition models that considered prevalence of drug
use in an individual’s age cohort (model 1), an increase in the
drug use of the cohort that an individual was in was associ-
ated with an increased individual risk of commencing drug use
(OR, 1.31 [95% CI, 1.29-1.33]; P < .001), transitioning from use
to abuse (OR, 1.11 [95% CI, 1.07-1.16]; P < .001), transitioning
from use to dependence (OR, 1.10 [95% CI, 1.03-1.18]; P = .007),
remitting from abuse (OR, 1.65 [95% CI, 1.54-1.77]; P < .001),
and remitting from dependence (OR, 1.65 [1.44-1.88]; P < .001).
With the exception of transitions to dependence, similar re-
sults were also observed when examining the prevalence of
cohort alcohol use (model 2; ORs: commencing use, 1.51 [95%
CI, 1.49-1.54]; P < .001; transitioning from use to abuse, 1.13
[95% CI, 1.07-1.19]; P < .001; remission from abuse, 1.44 [95%
CI, 1.30-1.61]; P < .001; remission from dependence, 1.67 [95%
CI, 1.12-2.50]; P = .01).
Individual-Level Substance Use History
At the individual level, having already developed alcohol abuse
was strongly associated with an increased risk of starting drug
use (OR, 10.78 [95% CI, 9.38-12.40]; P < .001), transitioning to
drug abuse (OR, 5.52 [95% CI, 4.40-6.92]; P < .001) or depen-
dence (OR, 3.80 [95% CI, 2.50-5.78]; P < .001), but also remit-
ting from drug abuse (OR, 1.36 [95% CI, 1.07-1.72]; P = .01) or
dependence (OR, 2.18 [95% CI, 1.32-3.62]; P = .003; model 3).
Similar results were found for having previously developed al-
cohol dependence (ORs: use, 12.81 [95% CI, 10.29-15.94];
P < .001; abuse, 6.48 [95% CI, 4.94-8.50]; P < .001; depen-
dence, 6.33 [95% CI, 4.12-9.73]; P < .001; remission from abuse,
1.49 [95% CI, 1.12-1.99]; P = .006; and remission from depen-
dence, 1.76 [95% CI, 1.09-2.84]; P = .02) and remission from
either alcohol abuse or dependence (ORs: use, 4.08 [95% CI,
3.20-5.21]; P < .001; abuse, 2.59 [95% CI, 1.78-3.78]; P < .001;
dependence, 2.01 [95% CI, 1.20-3.37]; P < .001; remission from
abuse, 2.25 [95% CI, 1.67-3.02]; P < .001; and remission from
dependence, 3.28 [95% CI, 1.99-5.40]; P < .001).
Considering the types of drugs used (model 4), cocaine in-
creased risk of transitioning to drug dependence (OR, 3.54 [95%
CI, 2.83-4.42]; P < .001), as did other drugs (OR, 3.25 [95% CI,
2.61-4.04]; P < .001); people with a history of cannabis use were
also more likely to remit from both drug abuse (OR, 1.68 [95%
CI, 1.36-2.08]; P < .001) and drug dependence (OR, 1.65
[95% CI, 1.20-2.27]; P = .002) than those who had not used
cannabis.
When considering only the number of drugs used (model
5), the use of 2 or more drug types increased the odds of tran-
sitioning to abuse (OR, 5.17 [95% CI, 4.66-5.73]; P < .001) and
dependence (OR, 5.99 [95% CI, 5.02-7.16]; P < .001) and re-
duced the odds of remitting from abuse (OR, 0.86 [95% CI, 0.76-
0.98]; P = .02).
Both Individual and Cohort Substance Use History
Table 4 presents the results obtained when including all indi-
vidual and cohort-level substance use variables considered in
the same model (also adjusting for sociodemographic vari-
ables). Once adjusting for an individual’s own prior sub-
stance involvement, an increase in their cohort’s drug use was
associated with an increased individual risk of commencing
drug use (OR, 1.12 [95% CI, 1.11-1.14]; P < .001) and remitting
from abuse (OR, 1.57 [95% CI, 1.46-1.69]; P < .001) and depen-
dence (OR, 1.59 [95% CI, 1.39-1.83]; P < .001) but was no lon-
ger associated with developing DUDs. Similar results were
observed for cohort alcohol use; an increase in prevalence
of cohort alcohol use was associated with increased indi-
vidual risk only of commencing drug use (OR, 1.28 [95% CI,






















































A, The cumulative age at onset curves for illicit drug use, abuse (without
hierarchy), dependence, remission from abuse, and remission from
dependence. Each curve includes respondents with and without the specific
diagnosis, where age at onset for the latter is censored at age of interview.
Estimates were scaled up to reach 100%. B, The cumulative curves for time to
transition between various drug stages. Each curve includes only respondents
with a diagnosis of the second stage. In A and B, persons with missing age at
onset of remission were excluded from associated curves (n = 147 for remission
from abuse; n = 104 for remission from dependence).
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1.26-1.31]; P < .001) and remitting from abuse (OR, 1.11 [95%
CI, 1.00-1.22]; P = .04). but was no longer associated with de-
veloping DUDs. Most other effects observed in the separate
models remained significant. Analyses at the country income
level were also investigated, the results of which are shown in
eTables 8-13 in the Supplement. Findings were largely consis-
tent between country income group analyses and the pooled
analyses presented in this study.
Discussion
The primary aim of the present study was to provide cross-
national data on the epidemiology of drug use, abuse, and de-
pendence and use a unique cross-national data set to exam-
ine transitions across levels of involvement with drug use, and
the extent to which alcohol and other drug use in an individu-
al’s birth cohort was associated with an individual’s risk of
these transitions, in addition to that person’s own prior in-
volvement in alcohol and drug use. At an individual level, ex-
tent of involvement with both alcohol and drug use was
strongly associated with risks of transitioning into drug abuse
and dependence, consistent with previous findings.31,32 Even
after having remitted from alcohol use disorder, individuals
remained at increased risk of beginning drug use and transi-
tioning to DUDs. Interestingly, individuals who had previ-
ously remitted from alcohol use disorder also had a higher
likelihood of remitting from DUDs than those who never
used alcohol.
After controlling for individual-level substance use his-
tory, extent of illicit drug use in an individual’s birth cohort was
associated with significantly increased risk of the individual
beginning drug use and remitting from DUDs. Cohort alcohol
use was also positively associated with commencement of il-
licit drug use and remission from drug abuse. That is, the more
people in an individual’s cohort who had a history of using those
substances, the greater the likelihood of the individual remit-
ting from the DUD after developing this disorder.
These findings speak to the social context in which sub-
stance use occurs. One of the most consistent findings in sub-
stance use research is that substance use of one’s peers is as-
sociated with a greater likelihood of involvement with
substance use for an individual.33 Here, we have further shown
that this is a generalized pattern, whereby not only substance
use among one’s friends matters, but also that of one’s peer
cohort more generally. This may be through multiple mecha-
nisms, such as associations with perceived drug use norms34
and increased opportunities to use substances.35 Further-
more, cohort substance use was shown not only to be associ-
ated with greater involvement with drugs, but rather to have
even stronger associations observed for transitions to remis-
sion from DUDs. This may reflect that individuals exposed to
higher cohort-level prevalence also have greater access to treat-
ment services than individuals exposed to lower cohort-level
prevalence, or perhaps that as cohort substance use in-
creases those who are transitioning to these disorders may be
less prone to problematic use or use disorders at the indi-
vidual level and, as a result, enter remission from those dis-
orders at a higher rate. These findings also suggest that the risk
for commencing drug use and remission from problems is not
constant but varies, in this case according to the extent to which
substance use is occurring among one’s peers.
Although higher rates of use in an individual’s cohort was
associated with an increased likelihood the individual will start
using drugs, there was no independent association of cohort
use with the transition to abuse or dependence once use had
begun. This suggests that while higher rates of use in an indi-
vidual’s cohort increase the likelihood that the individual will
start using drugs, the propensity to transition to problematic
use is not affected by such external variables; by contrast, we
found that it was affected by their own prior substance use his-
tory. Therefore, any intervention aiming to reduce substance
use within a cohort might also reduce individual-level risk for
transitioning into greater levels of involvement with drug use.
The type of substance such interventions should target war-
rants further investigation, especially considering that co-
hort alcohol use had a stronger association with commencing
drug use than cohort drug use did. However, implementation
would ideally be early in life and before opportunities to use
either substance arise (eTable 16 in the Supplement). If this oc-
curred, the smaller group of individuals who nonetheless de-
veloped DUDs despite the decrease in prevalence of use within
that cohort would be more refractive cases.
Limitations
This study provided detail regarding the prevalence and tim-
ing of various stages across the full trajectory of both alcohol
and illicit drug use, with clinically valid diagnoses and inclu-
sion of contextual factors not previously accounted for within
the literature. Data on age at onset for each stage were ob-
tained via retrospective self-report and may be subject to for-
ward telescoping, whereby participants are more likely to re-
port events as occurring closer to the point of the interview than
is accurate.36,37 However, this literature does not suggest that
the order of recalled events will be altered.
Investigating the interactive effects of the personal and
contextual variables on risk of transitioning involvement with
illicit drugs was beyond the scope of this article. However, fu-
ture work should investigate whether conditional associa-
tions exist between individual-level factors (eg, substance use,
history of mental disorder) and cohort contextual variables that
affect individuals’ risk of commencing use and transitioning
to greater involvement with drugs.
The WMH surveys have several important limitations.
There is not full representation of all countries, regions, coun-
try income levels or other country characteristics. There was
variation in response rates across countries, the year in which
the studies were administered, and possibly cross-national
differences in willingness to disclose personal information
about drug use and problems. Respondent information is sub-
ject to the limitations of recall inherent in retrospective re-
porting, leading to potential underestimates in lifetime preva-
lence. Survival bias may also contribute to downward bias in
lifetime estimates.
In addition to these general limitations, there are some limi-
tations specific to the assessment of DUDs. The WMH sur-
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veys are household surveys, which have limitations when used
to assess less common and more stigmatized behaviors. Il-
licit drug use can be a rare or geographically concentrated oc-
currence, and surveys such as the WMH surveys that rely on
stratified sampling methods are poorly suited to capturing con-
centrated geographic pockets of drug use. Furthermore, the
use of households as the primary sampling unit will not cap-
ture marginalized groups who do not live in traditional house-
hold contexts (eg, individuals who are homeless, in prison, in
the hospital, or in other nonhousehold accommodations).
These factors mean that prevalence rates presented here should
be considered lower-bound estimates; true lifetime preva-
lence of DUDs may be substantially higher.
Transition times to drug use disorders (DUDs) have been
shown to differ widely depending on substance class.38 Be-
cause most surveys assessed DUDs at the general illicit drug
level, it was not possible to evaluate transition times at the
drug-specific level. The estimates presented here therefore rep-
resent mean values of first transitions across all individuals who
use (single and multitype) illicit drugs.
Owing to the way in which symptom onset and recency is
assessed in the Composite International Diagnostic Interview,
it was only possible to assess remission at the time of interview.
Given the long-term nature of DUDs, additional information on
lifetime remission (ie, any period in life with an absence of symp-
toms for more than 12 months) may have made it possible to find
other variables were associated with remission.
Conclusions
Wehavefoundthat,acrosscountries,anindividual’spersonalrisk
of transitioning to greater involvement with drug use was asso-
ciated with their history of involvement with drugs and alcohol
and the substance use histories of their age cohort. These vari-
ables were associated with transitioning into and out of problem-
atic drug use, particularly when they are considered together, in
addition to a range of other sociodemographic correlates. These
findings have important implications for understanding of path-
ways into and out of problematic substance use.
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